This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProcess International: COVID-19 Therapeutic Development & Production
April 27-28, 2025
Delivered in a 100% Virtual FormatEastern Daylight Time (EST)

Andreas Kuhn, Ph.D.
Vice President RNA Biochemistry & Manufacturing at BioNTech RNA Pharmaceuticals GmbH
Speaker

Profile

Andreas Kuhn has worked in the field of RNA biochemistry and molecular biology for more than thirty years. His work on mRNA-based immunotherapies began in 2007 in the academic group of Ugur Sahin at the University Clinic Mainz, and Andreas joined BioNTech SE shortly after its founding in 2008. In his current role as Senior Vice President RNA Biochemistry & Manufacturing the main focus is expanding proprietary technologies to increase the efficacy of mRNA-based therapies and to optimize GMP-compatible manufacturing processes for RNA. He has co-authored numerous publications and patents ranging from basic research on RNA to its application as a therapeutic agent.“

Agenda Sessions

  • Keynote Opening Address: mRNA as a Platform Technology for Rapid Development of Vaccines Against Viral Infections – COVID-19 and Beyond

    12:45